BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
BioArctic (Nasdaq Stockholm: BIOA B) has entered into a significant collaboration agreement with Novartis Pharma AG to develop potential neurodegeneration treatments using BioArctic's proprietary BrainTransporter technology. The deal includes an upfront payment of $30 million to BioArctic.
Under the agreement, BioArctic will develop a new drug candidate combining their BrainTransporter technology with Novartis' proprietary antibody. If Novartis exercises their option following evaluation, they could pay up to $772 million in additional milestone payments plus mid-single digit royalties on future global sales. This marks BioArctic's third partnership utilizing their BrainTransporter platform, which enhances brain uptake of therapeutic agents through blood-brain barrier biology.
BioArctic (Nasdaq Stockholm: BIOA B) ha siglato un'importante collaborazione con Novartis Pharma AG per sviluppare potenziali terapie contro le neurodegenerazioni utilizzando la tecnologia proprietaria BrainTransporter di BioArctic. L'accordo prevede un pagamento iniziale di 30 milioni di dollari a BioArctic.
Secondo l'intesa, BioArctic svilupperà un nuovo candidato farmaco che combina la tecnologia BrainTransporter con un anticorpo proprietario di Novartis. Se Novartis eserciterà l'opzione dopo la valutazione, potrà versare fino a 772 milioni di dollari in ulteriori pagamenti legati a milestone e riconoscere royalty a metà singola cifra sulle future vendite mondiali. Si tratta della terza partnership di BioArctic che sfrutta la piattaforma BrainTransporter, progettata per migliorare l'assorbimento cerebrale dei farmaci attraverso la biologia della barriera emato-encefalica.
BioArctic (Nasdaq Stockholm: BIOA B) ha suscrito un acuerdo de colaboración importante con Novartis Pharma AG para desarrollar posibles tratamientos para la neurodegeneración utilizando la tecnología propietaria BrainTransporter de BioArctic. El acuerdo incluye un pago inicial de 30 millones de dólares a BioArctic.
En virtud del pacto, BioArctic desarrollará un nuevo candidato farmacológico que combina su tecnología BrainTransporter con un anticuerpo propietario de Novartis. Si Novartis ejerciera la opción tras la evaluación, podría abonar hasta 772 millones de dólares adicionales en hitos y pagar regalías de un dígito medio sobre las ventas mundiales futuras. Esta es la tercera alianza de BioArctic que utiliza la plataforma BrainTransporter, diseñada para aumentar la captación cerebral de agentes terapéuticos mediante la biología de la barrera hematoencefálica.
BioArctic (나스닥 스톡홀름: BIOA B)는 Novartis Pharma AG와 자사의 독점 기술인 BrainTransporter를 활용해 신경퇴행성 질환 치료제를 개발하기 위한 중요한 협력 계약을 체결했습니다. 이 계약에는 BioArctic에 대한 3,000만 달러의 선급금이 포함되어 있습니다.
계약에 따라 BioArctic는 BrainTransporter 기술과 노바티스의 독점 항체를 결합한 신규 약물 후보 물질을 개발합니다. 평가 이후 노바티스가 옵션을 행사하면, 추가로 7억7,200만 달러까지의 마일스톤 지급과 향후 전 세계 판매에 대한 중간 단일자리 비율의 로열티를 지불할 수 있습니다. 이는 혈액뇌장벽 생물학을 통해 치료제의 뇌 흡수를 향상시키는 BrainTransporter 플랫폼을 활용한 BioArctic의 세 번째 파트너십입니다.
BioArctic (Nasdaq Stockholm: BIOA B) a conclu un accord de collaboration important avec Novartis Pharma AG pour développer des traitements potentiels contre la neurodégénérescence en utilisant la technologie propriétaire BrainTransporter de BioArctic. L'accord prévoit un paiement initial de 30 millions de dollars à BioArctic.
Dans le cadre de cet accord, BioArctic développera un nouveau candidat-médicament combinant sa technologie BrainTransporter avec un anticorps propriétaire de Novartis. Si Novartis exerce son option après évaluation, elle pourrait verser jusqu'à 772 millions de dollars supplémentaires en paiements liés à des jalons ainsi que des redevances à un chiffre moyen sur les ventes mondiales futures. Il s'agit du troisième partenariat de BioArctic utilisant la plateforme BrainTransporter, conçue pour améliorer la captation cérébrale des agents thérapeutiques via la biologie de la barrière hémato-encéphalique.
BioArctic (Nasdaq Stockholm: BIOA B) hat eine bedeutende Kooperationsvereinbarung mit Novartis Pharma AG geschlossen, um potenzielle Therapien gegen Neurodegeneration mithilfe von BioArctics proprietärer BrainTransporter-Technologie zu entwickeln. Die Vereinbarung sieht eine Vorauszahlung von 30 Millionen US-Dollar an BioArctic vor.
Im Rahmen des Abkommens wird BioArctic einen neuen Wirkstoffkandidaten entwickeln, der die BrainTransporter-Technologie mit einem firmeneigenen Antikörper von Novartis kombiniert. Übt Novartis nach der Bewertung die Option aus, könnten bis zu 772 Millionen US-Dollar an weiteren Meilensteinzahlungen sowie Mid-Single-Digit-Royalties auf zukünftige weltweite Umsätze fällig werden. Dies ist die dritte Partnerschaft von BioArctic, die die BrainTransporter-Plattform nutzt, um die Gehirnaufnahme therapeutischer Wirkstoffe über die Biologie der Blut-Hirn-Schranke zu verbessern.
- Substantial upfront payment of $30 million
- Potential for additional milestone payments up to $772 million
- Future revenue stream through mid-single digit royalties on global sales
- Third successful partnership validates BrainTransporter technology platform
- Company retains rights to BrainTransporter platform for other applications
- Success depends on Novartis exercising their option after evaluation
- Development risks associated with early-stage neurodegeneration treatments
- BioArctic loses control over development if Novartis exercises option
Insights
BioArctic secures significant deal with Novartis worth up to $802M plus royalties, validating their blood-brain barrier technology platform.
This partnership represents a substantial financial boost for BioArctic with an immediate
The deal's significance extends beyond financials. This marks BioArctic's third partnership using their BrainTransporter platform, demonstrating growing industry recognition of this technology's potential to solve one of neuroscience's greatest challenges: delivering therapies across the blood-brain barrier. The platform's versatility is particularly valuable, as it can potentially be applied across multiple therapeutic modalities and neurological conditions.
For BioArctic, this agreement provides not only immediate capital but also strengthens their business model of partnering their delivery technology while retaining rights for other applications. The involvement of Novartis—a major pharmaceutical player with extensive neurological disease experience—provides significant validation. While the specific neurodegeneration target remains undisclosed, Novartis' willingness to commit substantial resources signals confidence in both the target's potential and BioArctic's technology to enhance delivery.
This deal follows the industry trend of major pharmaceutical companies seeking external innovation through partnerships rather than internal development alone, particularly for specialized drug delivery technologies that can enhance existing pipeline assets.
Novartis will evaluate the data generated during the initial collaboration and decide whether to exercise their option to license any drug candidate generated. If Novartis exercises their option, BioArctic will be eligible to receive additional payments of up to
Under the initial research collaboration, BioArctic will generate a new drug candidate combining the BrainTransporter technology with a Novartis proprietary antibody. Should Novartis decide to exercise their option following the evaluation of the generated drug candidate, Novartis will assume full responsibility for the global development and commercialization of the drug candidate and related products.
"I'm excited by today's announcement. Novartis shares our passion for science and helping patients with severe neurological disorders. With yet another BrainTransporter agreement it is becoming evident that this versatile platform has huge potential to improve many different projects, internally as well as externally generated, and could support companies across the field in their pursuit of helping people with brain disorders," said Gunilla Osswald, CEO at BioArctic.
"At Novartis, we are deeply committed to advancing science to help discover treatments for devastating nervous system disorders," said Sophie Parmentier Batteur, Head of Neurodegeneration Research at Novartis. "Collaborating with BioArctic allows us to explore the exciting potential of the BrainTransporter technology to promote brain uptake and optimize systemic delivery of novel therapeutic agents by leveraging the biology of the blood-brain barrier. Our focus is to pioneer innovative therapies that improve treatment outcomes by impacting disease progression, to provide meaningful therapies for patients with severe neurological conditions."
This agreement is the third[1] collaboration BioArctic has entered into with partners using the BrainTransporter technology. BioArctic retains all rights for use of the BrainTransporter platform outside of the scope of these three agreements. The BrainTransporter platform can be used in a number of different therapy areas for delivery of biologics and other modalities, giving BioArctic many potential future partnering opportunities.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on August 26, 2025, at 07.05 a.m. CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
About the BrainTransporter™ technology
BioArctic's BrainTransporter technology is a technology for facilitating the passage of biological drugs as for example antibodies into the brain using the transferrin receptor (TfR). Active transport of biotherapeutics across the blood brain barrier can result in broader brain distribution enabling better efficacy, improved safety profile and dosing convenience. The technology is being applied to several in-house drug projects, and could become part of future collaborations with other pharma companies.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.
[1] Previous agreements include a research evaluation agreement regarding BAN2802 with Eisai, and global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of |
View original content:SOURCE BioArctic
FAQ
What is the value of BioArctic's deal with Novartis?
What is BioArctic's BrainTransporter technology used for?
How many partnerships has BioArctic secured for its BrainTransporter technology?
What happens if Novartis exercises their option in the BioArctic agreement?
Does BioArctic retain any rights to the BrainTransporter platform?
